ArticleEndocrine2025
Pediatric pituitary adenomas: clinical features, treatment strategies, and management challenges.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePituitary adenomas (PAs) are rare in pediatric patients, with limited data. The study aimed to describe the specific characteristics of pediatric PAs and highlight the challenges in their management.
methodsWe conducted a retrospective review of patients diagnosed with PAs before age 18, who were followed at the reference center in Lyon, France, between 2010–2023.
results29 patients (19 females) were identified. Median age at diagnosis was 14 years (range: 10-17). 19 patients had prolactinomas, 4 corticotropinomas, 3 somatotropinomas and 3 non-functioning pituitary adenomas (NFPAs). The mean diagnosis delay was 13 months (median: 6, range: 0-70). The most common symptoms were headaches (34%), weight gain (34%) and visual field defects (31%). 17 prolactinomas received dopamine agonists, 4 underwent surgery. All corticotropinomas and somatotropinomas underwent surgery. Germline mutations were identified in 4 of 22 tested patients, including AIP (n = 1) and MEN1 (n = 3). Two patients exhibited resistance to first-line therapies. Two patients with corticotropinomas and two patients with somatotopinomas had growth or puberty impact.
conclusionPediatric PAs pose significant diagnostic and management challenges due to their rarity, variable clinical presentation, and impact on growth and puberty. Prolactinomas are the most common subtype, followed by corticotropinomas and somatotropinomas, while non-functioning adenomas are less frequent. Genetic mutations are relatively common and genetic assessment can inform management and family surveillance. Early diagnosis and a multidisciplinary approach are essential to optimize treatment, minimize complications, and ensure normal growth and pubertal development.
Indexed as
Identifiers
40974503What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.